Genus (LON:GNS – Get Free Report) released its quarterly earnings data on Thursday. The company reported GBX 110.30 EPS for the quarter, Digital Look Earnings reports. Genus had a net margin of 7.07% and a return on equity of 9.70%.
Here are the key takeaways from Genus’ conference call:
- FY 2026 results were strong: adjusted profit before tax and adjusted EPS each rose 35%, while free cash flow increased to £62 million and leverage fell to 0.4x.
- Genus announced a £60 million share buyback for FY 2027 and recommended a 10% increase in the full-year dividend to 35.2 pence per share, reflecting confidence in cash generation and future growth.
- PIC delivered broad-based growth, including 52% royalty-revenue growth in China and market-share gains, while the new China joint venture is expected to support further expansion in the world’s largest porcine market.
- PRP regulatory progress continued with approvals or favorable determinations in Argentina, Canada, Uruguay, and Peru; commercialization is now beginning in selected Latin American markets, although approvals in Mexico and China remain pending.
- Management expects FY 2027 underlying adjusted profit before tax to be only moderately higher, with growth weighted toward the second half due to weak agricultural markets, North American disease pressures, lower Brazilian growth, depressed dairy conditions, and higher PRP and product-development costs.
Genus Trading Down 5.3%
LON:GNS opened at GBX 2,115.68 on Thursday. Genus has a 1 year low of GBX 1,943 and a 1 year high of GBX 3,220. The stock has a market cap of £1.41 billion, a price-to-earnings ratio of 29.80, a PEG ratio of 2.87 and a beta of 0.90. The business has a fifty day moving average of GBX 2,223.11 and a 200-day moving average of GBX 2,382.24. The company has a debt-to-equity ratio of 51.73, a quick ratio of 1.08 and a current ratio of 2.25.
Insider Buying and Selling at Genus
Wall Street Analysts Forecast Growth
Separately, Berenberg Bank restated a “buy” rating and issued a GBX 3,350 price target on shares of Genus in a research report on Thursday. Three analysts have rated the stock with a Buy rating, According to MarketBeat.com, Genus has an average rating of “Buy” and an average price target of GBX 3,216.67.
Get Our Latest Stock Report on Genus
About Genus
Genus plc operates as an animal genetics company in North America, Latin America, the United Kingdom, rest of Europe, the Middle East, Russia, Africa, and Asia. The company operates through three segments: Genus PIC, Genus ABS, and Genus Research and Development. It sells breeding pigs and semen to breed pigs with various characteristics for pork production under the PIC brand. The company also sells bull semen and embryos to breed calves with various characteristics for milk and beef production under the ABS, Genus, and Bovec brands.
Featured Articles
- Five stocks we like better than Genus
- Life Time Keeps Beating Expectations, But Insiders Are Selling Into Strength
- Sezzle’s BNPL Growth Is Working, But the Stock Comes With a Catch
- Qualcomm’s Data Center Bet Looks More Real After Amazon’s AI Deal
- GE Aerospace’s $11.75B Deal Puts Howmet Aerospace in Focus
Receive News & Ratings for Genus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genus and related companies with MarketBeat.com's FREE daily email newsletter.
